Doxy-PEP is a strategy that uses the antibiotic doxycycline to prevent bacterial sexually transmitted infections after sex. The idea is simple: you take a single dose of doxycycline within 72 hours of a sexual encounter, and the antibiotic kills bacteria before an infection can take hold. In a landmark clinical trial conducted in San Francisco and Seattle, this approach reduced chlamydia infections by 88%, syphilis by 87%, and gonorrhea by 55%.
How Doxy-PEP Works
PEP stands for “post-exposure prophylaxis,” meaning prevention after exposure. Unlike daily medications you take on an ongoing schedule, doxy-PEP is event-driven. You take 200 mg of doxycycline as soon as possible after oral, vaginal, or anal sex, ideally within 72 hours. The dose should not exceed 200 mg in any 24-hour period.
Doxycycline is a tetracycline-class antibiotic that has been used for decades to treat bacterial infections. When taken shortly after exposure, it reaches high enough concentrations in your body to kill the bacteria that cause syphilis, chlamydia, and gonorrhea before they can multiply and establish an infection. It works best against chlamydia and syphilis. Its effectiveness against gonorrhea is lower, partly because some strains of gonorrhea are already resistant to tetracycline antibiotics.
Who Doxy-PEP Is Recommended For
The CDC issued its first clinical guidelines for doxy-PEP in 2024, and the recommendation is specific. It applies to gay, bisexual, and other men who have sex with men (MSM) and transgender women who have had at least one bacterial STI (syphilis, chlamydia, or gonorrhea) in the past 12 months. For people in this group, providers are encouraged to discuss doxy-PEP and offer it through shared decision-making.
MSM and transgender women who haven’t had a recent STI diagnosis but anticipate sexual activity with higher exposure risk can also discuss doxy-PEP with their provider, even though this group wasn’t directly studied in the clinical trials.
The CDC does not currently recommend doxy-PEP for cisgender women, cisgender heterosexual men, or transgender men. The evidence so far is insufficient to assess whether the benefits outweigh the risks in these populations. One trial that included cisgender women did not find the same protective effect, though the reasons are still being studied.
What Doxy-PEP Protects Against
Doxy-PEP targets three bacterial STIs:
- Chlamydia: The strongest protection, with an 88% reduction in the clinical trial. Chlamydia is highly susceptible to doxycycline, which is already a first-line treatment for the infection.
- Syphilis: An 87% reduction. Syphilis cases have been climbing in recent years, and doxy-PEP offers a meaningful layer of prevention for people at higher risk.
- Gonorrhea: A 55% reduction, which is moderate but statistically significant. Gonorrhea is trickier because many strains carry some level of tetracycline resistance.
Doxy-PEP does not protect against viral STIs like HIV, herpes, or HPV. It is meant to complement other prevention tools, not replace them.
How to Take It
The protocol is straightforward. After a sexual encounter, you take 200 mg of doxycycline in any formulation (tablets, capsules) as soon as you can, within the 72-hour window. Sooner is better. If you have multiple sexual encounters within a 24-hour period, you still take only one 200 mg dose for that day.
Providers typically prescribe enough doxycycline to cover one to three months of anticipated use, so you keep a supply on hand. Doxycycline is a widely available generic medication. In California, for example, state programs that cover HIV prevention medications have added doxy-PEP to their formularies without requiring additional paperwork or prior authorization. Coverage through private insurance varies, but the medication itself is inexpensive as generics go.
Side Effects
Doxycycline is generally well tolerated. The most common side effects are gastrointestinal: nausea, stomach upset, or diarrhea. These tend to be mild, especially with the intermittent dosing pattern of doxy-PEP rather than the daily dosing used to treat active infections.
Sun sensitivity is another known effect of doxycycline. Your skin may burn more easily while the drug is in your system. Taking it with food and a full glass of water can reduce stomach irritation, and wearing sunscreen helps manage the photosensitivity. People with known allergies to tetracycline antibiotics should not use doxy-PEP.
The Antibiotic Resistance Question
The biggest concern surrounding doxy-PEP is whether widespread prophylactic antibiotic use could fuel antibiotic resistance. This is not a theoretical worry. Both major clinical trials (DoxyPEP in the U.S. and DOXYVAC in France) found an increase in tetracycline-resistant gonorrhea among participants who took doxycycline.
Research published in The Lancet Infectious Diseases also found a gradual increase over time in drug-resistant staph bacteria (MRSA) among study participants in both the treatment and control groups, suggesting broader environmental pressures may be at play. Scientists have noted that tetracycline resistance in bacteria is often linked to resistance against other antibiotic classes, which could amplify the problem in ways that go beyond the STIs doxy-PEP is meant to prevent.
Researchers have described the population-level resistance risk as “hypothetical until confirmed or refuted by future studies,” but the early signals are concerning enough that ongoing monitoring is considered essential. This is one of the key tradeoffs that providers and patients weigh when deciding whether doxy-PEP makes sense. For individuals at high risk of repeated STIs, the immediate benefit of preventing infections may outweigh the uncertain long-term population-level risk. But the calculus could shift as more data comes in.
How Doxy-PEP Fits With Other Prevention
Doxy-PEP is often discussed alongside HIV pre-exposure prophylaxis (PrEP), and many people who are candidates for doxy-PEP are already taking PrEP. The two address different problems: PrEP prevents HIV, while doxy-PEP targets bacterial STIs. They can be used together. In fact, several of the clinical trials enrolled participants who were already on PrEP or living with HIV, since these groups often face the same STI exposures.
Regular STI screening remains important even with doxy-PEP. The protection is not 100%, particularly for gonorrhea, and catching any breakthrough infections early means faster treatment and less chance of passing the infection to someone else. The CDC guidelines assume that people using doxy-PEP will continue routine STI testing as part of their ongoing sexual health care.